712 IMPORT-201 (IMP-MEL): a phase 1 first-in-human dose finding/randomized phase 2 study of a novel iNKT agonist (PORT-2) and pembrolizumab for advanced melanoma and non-small cell lung cancer (NSCLC)

• David Thompson,
• Mark R Middleton,
• David J Pinato,
• Ian Walters,
• Robert Krämer,
• Uzi Gileadi,
• Nicholas Coupe,
• Justin Fairchild,
• Russell Poe,
• Carri Browne,
• Steven Innaimo,
• Carmela De Santo

Affiliations

David Thompson

4University of Oxford, Oxford, UK

Mark R Middleton

6Churchill Hospital and the University of Oxford, Oxford, UK

David J Pinato

2Imperial College London, London, Greater London, UK

Ian Walters

3iOx Therapeutics (a Portage Biotech company), Westport, CT, USA

Robert Krämer

3iOx Therapeutics (a Portage Biotech company), Westport, CT, USA

Uzi Gileadi

4University of Oxford, Oxford, UK

Nicholas Coupe

1Oxford University Hospitals, Oxford, Oxford, UK

Justin Fairchild

3iOx Therapeutics (a Portage Biotech company), Westport, CT, USA

Russell Poe

3iOx Therapeutics (a Portage Biotech company), Westport, CT, USA

Carri Browne

3iOx Therapeutics (a Portage Biotech company), Westport, CT, USA

Steven Innaimo

3iOx Therapeutics (a Portage Biotech company), Westport, CT, USA

Carmela De Santo

5University of Birmingham, Birmingham, UK